Jan 22, 2024
Warren Buffett is one of the most renowned investors of our time. So, it’s easy to forget that he was once a beginner too.
Buffett claims he bought his first stock at age 11 and spent his first eight years in the market focusing on stock price movements instead of studying the underlying companies.
Advertisement
“I had the whole wrong idea,” he said in a 2022 interview with journalist Charlie Rose. “I thought the important thing was to predict what a stock would do and predict the stock market.” Buffett says he even read books on technical analysis and charted stocks.
However, when he was 19 or 20 years old he read a book that would change his perspective forever: “The Intelligent Investor” by Benjamin Graham. Instead of charting stocks or "stock picking," Graham advocated for the valuation of underlying companies. His theory is that stock prices eventually follow the company’s financial performance.
To paraphrase Graham in another one of his books, "In the short run, the market is a voting machine, but in the long run, it is a weighing machine."
This simple philosophy shifted Buffett’s view on investing forever. “I realized that I was doing it exactly the wrong way,” he said. “I rejiggered my mind, when I read the book ...”
This philosophy has worked for Buffett over many decades and could serve retail investors looking for new opportunities in 2024. Here are two companies that seem misaligned with their stock prices this year.
GSK
GSK plc (GSK) is arguably undervalued. The stock currently has a forward price-to-earnings ratio of 9.91. It also offers a dividend yield of 3.5%.
The underlying business is in a transition. Activist hedge fund Elliott Management took a position in the company in 2021, pushing for changes to unlock value. In 2022, the company spun off its consumer health-care division into a new independent firm called Haleon. The spinoff was said to be financially beneficial for GSK. "One of the perks for GSK of the demerger was also a £7bn dividend which helped to reduce net debt of £19.8bn at the end of 2021," reported the Financial Times.
The company has been focused on its core pharmaceuticals and vaccine products. This seems to be delivering growth. In 2023, GSK raised its guidance for the year twice. It expects revenue to be as much as 13% higher and adjusted earnings per share to be as much as 20% higher than the previous year.
Advertisement
Strong sales and a low valuation should put this megacorporation on your radar of undervalued stocks.
Must Read
- Dave Ramsey warns nearly 50% of Americans are making 1 big Social Security mistake — here’s what it is and the simple steps to fix it ASAP
- Robert Kiyosaki begs investors not to miss this ‘explosion’ — says this 1 asset will surge 400% in a year
- Vanguard reveals what could be coming for U.S. stocks, and it’s raising alarm bells for retirees. Here’s why and how to protect yourself
Join 250,000+ readers and get Moneywise’s best stories and exclusive interviews first — clear insights curated and delivered weekly. Subscribe now.
Alphabet
Google’s parent company Alphabet (GOOGL) is in the midst of an interesting battle. Rivals have deployed billions into large language models and artificial intelligence that some say could erode Google’s dominance in the search market.
“[Google is] the 800-pound gorilla in this [market] … I want people to know that we made them dance,” Microsoft (MSFT) CEO Satya Nadella told The Verge shortly after OpenAI released ChatGPT.
Meanwhile, Jeff Bezos has bet on another AI startup, Perplexity AI, that’s also trying to capture some of this lucrative market.
For now, Google retains its crown as the king of search engines. The platform holds 91.61% market share, as of December 2023, according to data from StatCounter. Google is also actively competing in the AI race with its ChatGPT rival Bard, which is being gradually integrated across the company’s portfolio of apps.
These initiatives could help the company sustain its growth momentum. In the third quarter of 2023, the firm reported 11% growth in revenue and 41.5% growth in net income year-over-year. The stock trades at a forward price-to-earnings ratio of 22.22, which isn’t cheap but could be justified by this robust growth rate.
This fair-valued stock should certainly be on your watchlist for 2024 as the AI race heats up.
You May Also Like
- Turning 50 with $0 saved for retirement? Most people don’t realize they’re actually just entering their prime earning decade. Here are 6 ways to catch up fast
- This 20-year-old lotto winner refused $1M in cash and chose $1,000/week for life. Now she’s getting slammed for it. Which option would you pick?
- Warren Buffett used these 8 repeatable money rules to turn $9,800 into a $150B fortune. Start using them today to get rich (and stay rich)
- Here are 5 easy ways to own multiple properties like Bezos and Beyoncé. You can start with $10 (and no, you don’t have to manage a single thing)
Vishesh Raisinghani is a financial journalist covering personal finance, investing and the global economy. He's also the founder of Sharpe Ascension Inc., a content marketing agency focused on investment firms. His work has appeared in Moneywise, Yahoo Finance!, Motley Fool, Seeking Alpha, Mergers & Acquisitions Magazine and Piggybank.
